Analyst Reco. PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
32.25 ^USD	+3.86%		-2.30%	+17.02%

Apr. 30	North American Morning Briefing : More Earnings -2-	DJ
Apr. 29	Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28	Apr. 29	MT
TD Cowen Cuts Price Target on PTC Therapeutics to $30 From $32, Maintains Market Perform Rating	Mar. 01	MT
RBC Raises Price Target on PTC Therapeutics to $28 From $22, Keeps Sector Perform Rating	Mar. 01	MT
Cantor Fitzgerald Cuts PTC Therapeutics' Price Target to $45 From $51, Keeps Overweight Rating	Jan. 26	MT
Inflation is just the icing on the cake	Jan. 26
RBC Cuts Price Target on PTC Therapeutics to $22 From $27 Amid Negative Opinion on Translarna From European Medicines Agency Committee; Sector Perform Kept	Jan. 26	MT
RBC Raises Price Target on PTC Therapeutics to $27 From $23, Keeps Sector Perform Rating	Jan. 03	MT
Morgan Stanley Downgrades PTC Therapeutics to Underweight From Equalweight, Price Target is $28	Dec. 19	MT
North American Morning Briefing : Rate Decisions, -2-	23-10-30	DJ
Morgan Stanley Adjusts Price Target on PTC Therapeutics to $28 From $31, Maintains Equalweight Rating	23-10-27	MT
Barclays Trims Price Target on PTC Therapeutics to $25 From $26, Maintains Equalweight Rating	23-10-27	MT
Citigroup Downgrades PTC Therapeutics to Sell From Neutral	23-10-27	MT
RBC Cuts Price Target on PTC Therapeutics to $23 From $26, Keeps Sector Perform Rating	23-10-27	MT
Truist Securities Downgrades PTC Therapeutics to Hold From Buy, Price Target is $25	23-10-06	MT
Barclays Lowers Price Target on PTC Therapeutics to $26 From $44, Maintains Equalweight Rating	23-09-18	MT
Goldman Sachs Adjusts Price Target on PTC Therapeutics to $22 From $35, Keeps Sell Rating	23-09-18	MT
RBC Cuts Price Target on PTC Therapeutics to $26 From $49 Amid Negative Opinion on Translarna From European Medicines Agency Committee; Sector Perform Kept	23-09-18	MT
Citigroup Downgrades PTC Therapeutics to Neutral From Buy, Cuts Price Target to $29 From $55	23-09-18	MT
JPMorgan Lowers PTC Therapeutics Price Target to $53 From $70, Maintains Overweight Rating	23-09-15	MT
Morgan Stanley Cuts Price Target on PTC Therapeutics to $31 From $47, Maintains Equalweight Rating	23-09-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Analyst Reco.

Filters